Lakewood Capital Down 31% In Q1: Shorting The Following “Questionable Korean Biotech Companies”

Rupert Hargreaves

Published onApril 7, 2020

Anthony Bozza's Lakewood Capital Management ended the first quarter of 2020 with a net loss of 31.1%.

According to a copy of the hedge fund's Q1 letter, which ValueWalk has been able to review, the firm ended the month of March with long equity exposure of 98% and short exposure of 39.8% for net exposure of 58.2%.

If you’re looking for value stocks, and exclusive access to value-focused hedge fund managers, check out Hidden Value Stocks.

The top five equity positions in the portfolio accounted for 27.5% of equity capital at the end of March, and the top 10 positions in the portfolio...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Rupert Hargreaves

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for Hedge Fund Alpha

Lakewood Capital Down 31% In Q1: Shorting The Following “Questionable Korean Biotech Companies”

Login required to continue reading.

Get Your Business News